Please assess the completion status of the following clinical trial:

Trial Title: A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male or female participants not at childbearing potential \>=18 year-old or legal age of majority.~* Female participant if she has undergone sterilization at least 3 months earlier or was post-menopausal.~* Post-menopausal status was defined by having no menses for 12 months without an alternative medical cause.~* In females not treated with hormonal replacement therapy (HRT), menopausal status was confirmed by a high follicle stimulating hormone (FSH) level greater than 40 international units per litre (IU/L).~* In females on HRT and whose menopausal status was in doubt (i.e. in women aged less than 45 years), a highly effective contraception methods was required. Contraception was used during the whole study and for at least seven days corresponding to time needed to eliminate study treatment.~* Symptomatic stable angina pectoris (typical or atypical symptoms with an average of at least bi-weekly episodes over the past month).~* Participants with non-obstructive (\<50% stenosis) coronary arteries or intermediate stenosis (between 50 and 70%) should have fractional flow reserve (FFR) \>0.80 or instantaneous wave-free ratio (iFR) \>0.89 on angiogram, documented within the previous 24 months\*. In participants with stenting, a minimum diameter stenosis of \<10% is required.~or Coronary computed tomography angiography (CCTA) with finding of non-obstructive coronary arteries within the past 24 months\* in participants without previous percutaneous coronary intervention (PCI).~\*Note: in cases of clinically suspected progression of atherosclerosis as per the Investigator, a more contemporary (i.e., 6 months) evidence should be provided.~or CCTA performed during screening period, with finding of non-obstructive coronary arteries, in participants diagnosed with microvascular angina (MVA) and stable angina without previous PCI who did not have a coronary angiogram or CCTA in the previous 24 months but between 24 months to 5 years.~- Baseline global coronary flow reserve (CFR) (measured during the study) assessed by 13N-ammonia or 82Rubidium positron emission tomography (PET) scan \<2.0.~Exclusion criteria:~* Any use of nitrates (except short-acting nitrates) and/or dipyridamole and/or phosphodiesterase type 5 (PDE 5) inhibitors within one week prior to baseline PET scan or anticipated to be used during the study.~* Esophageal dysmotility or esophagitis.~* Participants with acute coronary syndrome (ACS) (myocardial infarction \[MI\] and/or unstable angina) in previous 3 months.~* Unsuccessful or incomplete coronary revascularization with residual obstructive stenosis or coronary artery disease (CAD) progression in native vessels as documented on invasive coronary angiography (\>=50% stenosis) within 24 months of enrollment.~* Percutaneous coronary intervention performed at the time of an ACS (MI or unstable angina) in the previous 12 months.~* Recent PCI within the past 3 months.~* Participants with history of coronary artery bypass grafting (CABG).~* Recent (\<=3 months) major surgery (i.e. valvular surgery, surgery for congenital heart disease), stroke, transient ischemic attack \[TIA\], sustained ventricular arrhythmia, clinically significant structural heart disease (moderate-severe valvular disease, hypertrophic cardiomyopathy, congenital heart disease, pulmonary hypertension).~* Regional local flow abnormal perfusion defects at baseline PET scan\*.~  \*Note: if contemporary evidence with invasive coronary angiography or CCTA demonstrates non-obstructive coronary arteries or if the regional local flow abnormal perfusion defect on PET scan is consistent with previous studies then participant qualifies for the study.~* Participants with cardiac conduction abnormalities (second or third degree atrioventricular \[AV\] block, sick sinus syndrome, symptomatic bradycardia, sinus node disease) except in participants fitted with a functioning pacemaker.~* History or known carotid stenosis:~* Carotid stenosis (\>50%) or~* History of carotid stenosis in participants with previous symptoms.~* Contraindication or known hypersensitivity to adenosine or regadenoson.~* Contraindication to aminophylline.~* Contraindication to vasodilator stress PET scan and/or CCTA if CCTA needed during screening.~* Inability to discontinue treatment with methylxanthines treatment within 24 hours prior to PET scan.~* Participant unable to read, understand and fill a questionnaire without any help (eg, partially visually impaired or blind).~* Systolic blood pressure (SBP) \<110 millimeter of mercury (mmHg) at baseline.~* Presence at baseline of symptomatic orthostatic hypotension (SBP decrease of 20 mmHg or more at Minute 3 or Minute 5 between seated and standing position), or asymptomatic orthostatic hypotension with a decrease in SBP equal or greater than 30 mmHg at Minute 3 or Minute 5 when changing from the seated to the standing position.~* Renal impairment with estimated glomerular filtration rate (eGFR) \<50 milliliter/minute/1.73 square meter (mL/min/1.73 m\^2) at screening and baseline.~* Drug-induced liver injury related criteria:~* Underlying hepatobiliary disease.~* Alanine Aminotransferase (ALT) \>3 times the upper limit of normal (ULN).~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo for 4 weeks.
- SAR407899 (Type: EXPERIMENTAL): SAR407899 with dose titration over 4 weeks administration (3 week titration phase + 1 week maintenance phase).

Based on this trial design, predict the completion outcome and termination type (if applicable).